Onco Actu du 24 mars 2016

	1. Biologie
CRISPR And Beyond: UCSD-Doudna Work Attracts Paul Allen's Millions [Xconomy] “If we could identify a cell by its RNA content, we should be able to track where it goes.” The same goes for cancer cells, Yeo says—which means tracking their RNA might eventually lead to better ways to intercept or modify those cells.
	3.1 Tabac
Cigar industry faces the possibility of unprecedented regulation [STAT] “Cigars are not a path to nicotine addiction,” said J. Glynn Loope, executive director of Cigar Rights of America, which represents manufacturers and smokers. “We think we should be treated in a wholly different manner than cigarettes and e-cigarettes.”
WHO urges India to implement larger health warnings on cigarette packs [Reuters] Henk Bekedam, the WHO's India representative, said the current debate on reducing the size of tobacco health warnings in India was "worrisome".
	5. Traitements
Many Targeted Cancer Therapies Suppress T Cell Immune Responses [Wistar Institute] New research from The Wistar Institute demonstrated that dozens of these targeted therapies suppressed the activity of T cells that could actually help fight tumors. While studying the FDA-approved targeted therapy trametinib, the researchers also found that pairing it with a signaling protein “superagonist” stimulated T cell activity while preserving the cancer-blocking effects of the cancer treatment.
Seeking kinder ways to tackle childhood cancer [The Institute of Cancer Research] Our research could reshape how we treat rhabdomyosarcoma, making huge, long-lasting improvements to young patients’ lives.
	5.10 Traitements - Essais
ASCO Tool Found to be an Effective and Easy Way to Manage and Monitor Clinical Trial-Associated Workload [ASCO] The Tool enables research site administrators to more effectively monitor and manage staff capacity, productivity, and needs. It also provides reports specific to protocols, sites, and staff.
	5.2 Pharma
Tarveda Formally Spins Out Placon to Advance Platinum Cancer Drugs [Xconomy] Placon, based in Cambridge, MA, is advancing what had been Tarveda’s lead drug, a molecule called BTP-114. It’s meant to be a more targeted, next-generation version of the platinum-based chemotherapy compounds that are often used in cancer treatment.
	5.2.1 Pharma - Partenariats
Roche Looks Outside Its Labs to Expand Cancer Drug's Potential [Bloomberg] The partnerships with Kite and J&J mark a small shift in Roche’s strategy, which has emphasized using its own, large pool of potential compounds and medicines to find new cancer-drug combinations.
	5.2.3 Pharma - économie
Roche CEO Schwan beats Novartis chief with $12.3M in 2015 pay, but U.S. companies shell out more [FiercePharma] Compared with their U.S.-based biopharma rivals, however, both CEO's compensation packages rank far lower. For instance, AbbVie recently reported more than $20 million in 2015 compensation for chief Richard Gonzalez, and that was down from $22 million in 2014.
	5.3 Traitements - FDA, EMA,...
FDA Updates Breakthrough Therapy Program: Meet the Preliminary Breakthrough Therapy Designation Request [FDA Law Blog] FDA is often asked by Sponsors whether the Agency agrees that the therapy should be designated as a breakthrough therapy. The Preliminary BTDR Advice Request appears to be a way to formalize these inquiries and encourage Sponsors to open a dialogue about BTD eligibility before submitting an official BTDR.
	5.5 ASCO
Clifford A. Hudis Named ASCO’s Next Chief Executive Officer [ASCO] Dr. Hudis is among the world’s most recognized experts in breast cancer treatment and prevention, and is a former President (2013-2014) and Board member of ASCO.
	6. Lutte contre les cancers
The Who's Roger Daltrey: Teens with cancer deserve better [STAT] Daltrey, now 72, sat down with STAT after the panel discussion to explain his interest in teen cancer — which started with his involvement in a British charity, Teenage Cancer Trust — and his views on the biggest medical initiatives in Washington, including the House-passed 21st Century Cures Act and Vice President Joe Biden’s cancer “moonshot” effort.
	6.1 Observation
How much does chemo impact fertility? [Fred Hutch] Although treatment data was from before 2000, most of the 14 chemotherapy drugs examined by the team of researchers are still commonly used, Chow said.
	6.10 Politiques
India defends right to issue drug 'compulsory licenses' [Reuters] "There have been recent media reports that the Government of India has privately assured that it will not issue any more compulsory licenses. It is hereby clarified that such reports are factually incorrect," the ministry said in the statement late on Tuesday.
	6.11 Patients
One man's desperate quest for a brutal appendix cancer surgery [STAT] To appendix cancer patients, Phillips’s frenzied medical crusade is familiar. Most are told in no uncertain terms that their condition is fatal. But the Internet tells them otherwise.
	6.6 Publications
On pastrami and the business of PLOS [it is NOT junk] Throughout PLOS’s history there were times we had to choose between abstract ideals and the reality of making PLOS a successful business, and I think, overall, we’ve done a good, but far from perfect, job of balancing this tension.